Introduction
============

Diabetes mellitus (DM) is a common endocrine metabolic disorder all over the world ([@b1-mmr-17-01-0103]--[@b3-mmr-17-01-0103]). DM is characterized by chronic inflammation, which can cause oxidative stress and long-term chronic dysfunction ([@b4-mmr-17-01-0103]--[@b8-mmr-17-01-0103]). Previous study has showed that increased ROS production could contribute to the low antioxidative capacity of β-cells ([@b5-mmr-17-01-0103]). Normally, cells could use the superoxide dismutase (SOD), catalases (CAT), and peroxiredoxins to combat ROS damage. Thus, oxidative stress could be reduced in diabetic mice by increasing SOD production in previous description ([@b9-mmr-17-01-0103],[@b10-mmr-17-01-0103]). Specifically, the SOD and CAT concentration are regulated by nuclear transcription factor-like 2 (Nrf2), resulting in the inhibition of oxidative stress and lipid accumulation in DM ([@b11-mmr-17-01-0103]).

Curcumin is extensively used in Asian countries, and a wide range of pharmacological properties has been attributed to it ([@b12-mmr-17-01-0103]). Previous studies have reported that curcumin has a number of beneficial effects and used as an antioxidant and anti-inflammatory agent ([@b13-mmr-17-01-0103]--[@b17-mmr-17-01-0103]). Shehzad *et al* noted the beneficial effects of curcumin on obesity-related-metabolic syndrome ([@b18-mmr-17-01-0103]). Given its beneficial effects, safety and cost-effectiveness, curcumin could be used to treat diabetes and complications ([@b8-mmr-17-01-0103],[@b18-mmr-17-01-0103]). Moreover, previous studies have reported that curcumin can increase oxygen consumption and the activity of CAT, glutathione peroxidase (GSH-Px) and SOD, decrease lipid levels and protein oxidation to protect against oxidative stress in a high-fat diet induced diabetic rat ([@b15-mmr-17-01-0103],[@b19-mmr-17-01-0103]--[@b21-mmr-17-01-0103]). GSH-Px, CAT, SOD and HO-1 are important parts of the antioxidant response element (ARE), which is increased by activating Nrf2 ([@b22-mmr-17-01-0103],[@b23-mmr-17-01-0103]). However, the network of curcumin antioxidant effects resulting from the activation of the Keap1-Nrf2-ARE signaling pathway associated with diabetes has not been completely elucidated. Presented here is an investigation of the capacity of curcumin to inhibit oxidative stress in a rat model of type 1 diabetes by activating the Keap1 signaling pathway.

Materials and methods
=====================

### Reagents

Streptozotocin and curcumin were purchased from Sigma Company (USA). The kits of blood glucose, GSH-Px, SOD, CAT and malondialdehyde (MDA) were purchased from Nanjing Jiancheng Biologic Project Company (Nanjing, China). The kits of insulin and glucagon radioimmunoassay were procured from North Institute of Biological Technology (Beijing, China).

### Animals and ethics statement

Seven-week-old male Sprague-Dawley (SD) rats (209±8 g) were obtained from SLAC Laboratory Animal Company (Shanghai, China). After one-week of acclimatization to the laboratory conditions, all male SD rats were weighed and randomly assigned. They were fed on standard food pellets and tap water under controlled environmental conditions (temperature: 23±2°C) and a 12 h light/dark cycle. All animal experimental procedures were approved by Fujian Agriculture and Forestry University Animal Care and Use Committee. All animal handling procedures were performed in strict accordance with the care of laboratory animals of the Fujian province Zoological Society.

### Experimental design

The fifty-four SD rats were divided as follows: group I (NC, *n*=18) was a control group, group II (DC, *n*=18) was a diabetes control group, and group III (Diab-Cur, n=18) was a normal diet plus 1.0% curcumin (weight ratio) group. Considered the experiment of the power analysis, a large sample size of 18 per group was used. All animals were fed for 21 days. The rat model of diabetes was established by injecting Streptozotocin (STZ) intraperitoneally at a dose of 80 mg/kg ([@b24-mmr-17-01-0103]), administered daily for three days. The rats in group I were also injected intraperitoneally with the buffer alone. After treatment, the animals were fasted 12 h and then the fasting blood glucose levels of all rats were measured. The rats were considered diabetic when the fasting blood glucose levels exceeded 11.1 mmol/l. After 7 days, the rat health was worse than that before and the number of rats that died was from the study (8/18 in Group II and 6/18 in Group III). Thus, we were used the insulin 6 U/kg treatment once every two day until the end of the experiment but the last time was not used the insulin treatment in order to collected the samples. In order to equal number in rats, the number of rats were excluded from the study (8/18 in Group I and 2/12 in Group III) at the end of experiment.

### Blood and tissue collection

During the experiment, blood sample was collected for biochemical measurement every three days starting on day 3. The body weight and food and water intake of each rat were recorded (once every day during the experiment). The animals were fasted 12 h on the last day, given mild ether anesthesia (1%, 2 min) and killed by broken neck after collecting the blood sample. The plasma was collected in heparin sodium vessels by centrifugation at 3,500 rpm for 15 min, and was subsequently stored at −70°C until assayed. Tissue samples from heart, liver and leg muscle were immediately collected, weighed, and stored at −80°C until analysis.

### Blood analyzed

Blood glucose levels were determined by the glucose oxidase method. The concentrations of MDA and the activities of SOD (cat. no. A001-3), GSH-Px (cat. no. A006-1) and CAT (cat. no. A007-2) were determined using assay kits by spectrophotometrically. All produces were performed according to the manufacturer\'s instruction.

The concentrations of insulin and glucagon were measured using a radioimmunoassay kit (cat. no. 060514) according to the manufacturer\'s instructions. The ^125^I-Ins (or ^125^I-Glu) and rabbit anti-Ins (or anti-Glu) antibody were mixed with the samples, standards and controls and incubated for 24 h. After centrifuging for 15 min, a separating medium was removed and the sediment was saved for measurement on a γ-counter.

### RNA extraction, cDNA synthesis and qPCR

Liver sample was collected by slaughter and immediately frozen in liquid nitrogen on day 21. RNA was extracted and isolated from liver tissue using TRIzol reagent (TaKaRa, Dalian, China). The concentration of RNA was quantified in a spectrophotometer (Eppendorf-Biotech, Hamburg, Germany) by measuring the absorbance at 260 nm. mRNA expression was measured by qRT-PCR according to our previous study ([@b25-mmr-17-01-0103]) and performed using a MyiQ2 Real-time PCR system (Bio-Rad, Hercules, USA). Primers designed using Primer 5.0 software and synthesized in the Sangon Biotech (Shanghai, China) and listed in [Table I](#tI-mmr-17-01-0103){ref-type="table"}.

### SDS-PAGE and western blot analysis

The protein was extracted from frozen liver tissue. Cytoplasmic proteins and nuclear proteins were fractionted using a CelLytic^™^ NuCLEAR^™^ Extraction kit (Sigma-Aldrich Co. LLC, Beijing, China) ([@b26-mmr-17-01-0103]). The protein concentration was measured using the Bradford assay. Subsequently, 50 µg protein samples were heated for 10 min at 98°C and subjected to electrophoresis on a 10% SDS-PAGE gel to separate the proteins. The separated proteins were transferred to nitrocellulose membranes (Bio-Trace, USA) and blocked in 5% nonfat milk powder for 2 h at 20°C. After blocking, the protein was incubated overnight at 4°C with anti-keap1 antibody (1:1,500, Abcam) and anti-Nrf2 antibody (1:1,000, Abcam). After washing three times, the corresponding HRP conjugated secondary antibodies were incubated at 4°C. The anti-GADPH antibody (1:1,000, Abcam) and lamin B (1:1,000, Abcam) was used served as loading controls of cytoplasmic and nuclear fractions, respectively. Finally, blots were washed and detected by enhanced chemiluminescence (ECL) using the LumiGlo substrate (Pierce, USA) and Clarity Western ECL Substrate (BioRad, USA).

### Statistical analysis

The statistical significance was analyzed by Tukey\'s test model of ANOVA (SPSS-20.0 software; IBM Corp., Armonk, NY, USA). P\<0.05 was considered to indicate statistical significance. The results were expressed as mean ± SE.

Results
=======

### Body weight, food and water intake, blood glucose, and plasma insulin and glucogan concentration

After 21 days of the experiment, the body weight (BW) of the rats was significantly reduced in the Diab-Cur group (P\<0.05) and DC group (P\<0.01) compared with the NC group. However, the BW of rats was markedly increased in the Diab-Cur group (P\<0.05) compared to that in the DC group ([Fig. 1A](#f1-mmr-17-01-0103){ref-type="fig"}). The food and water intake was distinctly increased in the Diab-Cur group compared with NC group ([Fig. 1B and C](#f1-mmr-17-01-0103){ref-type="fig"}). After the 9th day, curcumin treatment obviously reduced the food intake on days 12 (P\<0.05), 15 (P\<0.01), 18 (P\<0.01), and 21 (P\<0.01), and reduced the water intake on days 12 (P\<0.05), 15 (P\<0.05), 18 (P\<0.01), and 21 (P\<0.01) compared with the DC group.

The concentration of blood glucose was obviously increased in the DC group and Diab-Cur group compared with the NC group ([Fig. 1D](#f1-mmr-17-01-0103){ref-type="fig"}). After day 9, the blood glucose level was significantly reduced on days 12 (P\<0.001), 15 (P\<0.001), 18 (P\<0.01), and 21 (P\<0.001) in the Diab-Cur group. The plasma insulin concentration was markedly decreased (P\<0.05) in the DC and Diab-Cur groups compared with the NC group, whereas the plasma insulin concentration in the Diab-Cur group was obviously higher than those in the DC group (P\<0.05, [Fig. 1E](#f1-mmr-17-01-0103){ref-type="fig"}). Furthermore, the plasma glucagon levels were significantly increased in the Diab-Cur group (P\<0.05) and DC group (P\<0.01) compared with those in the NC group rats, but the glucagon levels were significantly reduced (P\<0.05) in the Diab-Cur group compared with the NC group ([Fig. 1F](#f1-mmr-17-01-0103){ref-type="fig"}).

### Tissue glycogen content

As shown in [Table II](#tII-mmr-17-01-0103){ref-type="table"}, the glycogen concentrations of hepatic, myocardial and muscle tissue in the DC group were significantly decreased (P\<0.05) compared with the NC group, whereas the hepatic, myocardial and muscular glycogen levels were significantly increased in the Diab-Cur group (P\<0.05). Although the levels of hepatic and muscular glycogen were obviously decreased in the Diab-Cur group compared with NC group rats (P\<0.05), the myocardial glycogen levels were significantly increased (P\<0.05).

### Plasma SOD, GSH-Px, CAT and MDA level

As shown in [Table III](#tIII-mmr-17-01-0103){ref-type="table"}, there was an obvious reduction of SOD activity in the DC group compared with the NC group (P\<0.01), but curcumin treatment significantly increased SOD activity compared with the levels in both the NC and DC groups (P\<0.05 and P\<0.01, respectively). Compared to the NC group, the levels of GSH-Px, CAT and MDA in the DC and Diab-Cur groups were significantly increased (P\<0.05). Compared with DC group, the levels of GSH-Px (P\<0.01), CAT (P\<0.05) and MDA (P\<0.01) were significantly decreased in the Diab-Cur group.

### Antioxidase gene expression

As shown in [Fig. 2](#f2-mmr-17-01-0103){ref-type="fig"}, the results showed that expression levels of the antioxidase genes NAD (P)H quinone dehydrogenase 1 (*NQO-1*), *CAT*, *GSH-Px*, and *HO-1* were significantly upregulated in the Diab-Cur group compared with those in the NC (P\<0.05) and DC groups (P\<0.05). However, the antioxidase gene expression levels of *GSH-Px*, *HO-1* and *NQO-1* were markedly downregulated (P\<0.05) in the DC group. Notably, the gene expression of *SOD1* was completely contrary to the expression profiles of the other antioxidase genes.

### Protein expression

As illustrated in [Fig. 3A](#f3-mmr-17-01-0103){ref-type="fig"}, compared with the NC group, the protein expression level of keap1 was significantly upregulated in the Diab-Cur group rats (P\<0.01), but downregulated in the DC group (P\<0.05). Compared with the DC group, protein expression of keap1 was significantly upregulated in the Diab-Cur group (P\<0.001). As demonstrated in [Fig. 3B](#f3-mmr-17-01-0103){ref-type="fig"}, curcumin treatment decreased cytosolic concentrations of Nrf2 while increasing nuclear accumulation of Nrf2.

Discussion
==========

STZ-induced type 1 diabetes models are characterized by a loss of β-cells in the islets of Langerhans in the pancreas, which leads to insulin deficiency and metabolic disease caused by elevated blood sugar ([@b7-mmr-17-01-0103],[@b8-mmr-17-01-0103],[@b27-mmr-17-01-0103],[@b28-mmr-17-01-0103]). In this study, the results showed that BW was markedly decreased and that the blood glucose levels and food and water intake were clearly increased in rat with type 1 diabetes. Especially, the blood glucose levels were elevated more than twofold in the DC group compared with those of control group, whereas curcumin-treated significantly decreased the concentrations of blood glucose ([Fig. 1D](#f1-mmr-17-01-0103){ref-type="fig"}). Previous studies have shown that curcumin has anti-diabetic activities and that dietary supplements containing curcumin affect glycemic control ([@b12-mmr-17-01-0103],[@b29-mmr-17-01-0103],[@b30-mmr-17-01-0103]). Moreover, curcumin supplementation to rat model in diabetes showed that plasma insulin concentration was obviously increased and plasma glucagon levels were markedly reduced ([@b30-mmr-17-01-0103]). In this study, a decrease of 58% in the level of plasma insulin and an increase of 52% in the level of plasma glucagon when compared to the control group were observed ([Fig. 1E and F](#f1-mmr-17-01-0103){ref-type="fig"}). But, curcumin-treated rat model significantly increased plasma insulin levels ([Fig. 1E](#f1-mmr-17-01-0103){ref-type="fig"}) and decreased plasma glucagon levels ([Fig. 1F](#f1-mmr-17-01-0103){ref-type="fig"}). At the same time, curcumin treated diabetic animals also showed a significant increase in the hepatic and myocardial glycogen concentrations ([Table II](#tII-mmr-17-01-0103){ref-type="table"}). These results imply that curcumin could reduce hyperglycemia.

However, the autoxidation of glucose could increase due to free radicals production with chronic hyperglycemia during the diabetes, which is involved in β-cell dysfunction ([@b5-mmr-17-01-0103],[@b6-mmr-17-01-0103],[@b27-mmr-17-01-0103]). β-cell dysfunction could lead to β-cell death, which depends on the subsequent poly (ADP-ribose) synthetase activation and DNA alkylation ([@b5-mmr-17-01-0103],[@b6-mmr-17-01-0103],[@b31-mmr-17-01-0103]--[@b33-mmr-17-01-0103]). Moreover, decreases in the expression of antioxidant enzymes and the range of minimum antioxidant competence of β-cells could lead to free radical damage ([@b28-mmr-17-01-0103],[@b34-mmr-17-01-0103]). Previous results have demonstrated that the activity of the antioxidant enzymes SOD, CAT and GSH-Px can prevent oxidative stress ([@b35-mmr-17-01-0103]). Importantly, SOD and CAT play important roles in the detoxification of O^2-^ ([@b35-mmr-17-01-0103],[@b36-mmr-17-01-0103]). GSH-Px can regulate the intracellular redox system to defend cells against oxidative stress ([@b37-mmr-17-01-0103]). Additionally, through the dismutation and generation of hydrogen peroxide, SOD destroys the superoxide radical, whereas SOD activity is attenuated by catalase or glutathione peroxidase ([@b36-mmr-17-01-0103],[@b38-mmr-17-01-0103],[@b39-mmr-17-01-0103]). Recently, reports have shown that pancreatic β-cells were not damaged by oxidative stress under diabetic conditions by increasing catalase activity ([@b5-mmr-17-01-0103],[@b38-mmr-17-01-0103]). In the present study, plasma MDA concentration, GSH-Px and CAT activity were significantly increased and indicated that an impairment in antioxidant defenses may increase the scavenging oxygen free radicals ([@b36-mmr-17-01-0103],[@b40-mmr-17-01-0103],[@b41-mmr-17-01-0103]) or enhance the antioxidant capacity ([@b19-mmr-17-01-0103],[@b20-mmr-17-01-0103],[@b30-mmr-17-01-0103]). In a previous study, activation of the Keap1-Nrf2-ARE pathway was shown to reduce oxidative stress ([@b42-mmr-17-01-0103]). Additional studies have demonstrated that Nrf2 signaling, as activated by salvianolic acid, can be effective against oxidative stress ([@b22-mmr-17-01-0103],[@b43-mmr-17-01-0103]--[@b45-mmr-17-01-0103]). In the present study, we showed that Nrf2 signaling was activated in curcumin-treated rats. First, the activities of the keap1-Nrf2 complex were reduced, which led to the uncoupling of keap1-Nrf2 in curcumin-treated rats. Second, Nrf2 was stabilized and transported into cell nuclei, leading to the transcription of several ARE-regulated genes (*HO-1*, *NQO-1*, *GSH-Px*, *CAT* and *SOD1*). Intriguingly, previous studies have shown that upregulating the expression of Nrf2 protein in the nuclear and increased the expression of *HO1* and *NQO-1* ([@b46-mmr-17-01-0103]). In this study, the expression of the Nrf2 protein and ARE-regulated genes was upregulated in curcumin-treated rats compared to those in the DC group. Importantly, the activation of Nrf2 by curcumin dramatically relieved oxidative stress in the STZ-induced diabetic rat model.

In conclusion, a diagram illustrating the proposed mechanism of action of curcumin is shown in [Fig. 4](#f4-mmr-17-01-0103){ref-type="fig"}. We propose that curcumin may be exerts protective effects in STZ-induced diabetes by activating Keap1-Nrf2-ARE signaling through both a decrease in blood glucose concentration and an increase in the transcription of several antioxidant genes.
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![Body weights, food and water intake, blood glucose, and plasma insulin and glucogan concentration. (A) Body weights of rats; (B) food intake; (C) water intake; (D) blood glucose concentration; (E) plasma insulin concentration; (F) plasma glucagon concentration. Data are presented as the mean ± standard error. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. NC group; ^\#^P\<0.05, ^\#\#^P\<0.01 and ^\#\#\#^P\<0.001 vs. DC group. NC, negative control; DC, diabetic control; Diab-Cur, diabetic with 1.0% curcumin treatment.](MMR-17-01-0103-g00){#f1-mmr-17-01-0103}

![Gene expression of several antioxidant response element-regulated genes. RNA was extracted from the liver, reverse-transcribed to cDNA and analyzed by reverse transcription-quantitative polymerase chain reaction for gene expression. The experiments used 18 samples from each group. Data are presented as the mean ± standard error. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. NC group; ^\#^P\<0.05, ^\#\#^P\<0.01 and ^\#\#\#^P\<0.001 vs. DC group. NC, negative control; DC, diabetic control; Diab-Cur, diabetic with 1.0% curcumin treatment; HO-1, heme oxygenase-1; NQO-1, norvegicus NAD(P)H quinone dehydrogenase 1; GSH-Px, glutathione peroxidase; CAT, catalase; SOD1, superoxide dismutase 1.](MMR-17-01-0103-g01){#f2-mmr-17-01-0103}

![Protein levels of the Keap1-Nrf2-ARE pathway. (A) Keap1 protein; (B) Cytosolic and nucleic Nrf2 levels. The experiments used 18 samples from each group. Data are presented as the mean ± standard error. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. NC group; ^\#\#^P\<0.01 and ^\#\#\#^P\<0.001 vs. DC group. Keap1, Kelch-like ECH-associated protein 1; Nrf2, nuclear factor (erythroid-derived 2)-like 2; NC, negative control; DC, diabetic control; Diab-Cur, diabetic with 1.0% curcumin treatment.](MMR-17-01-0103-g02){#f3-mmr-17-01-0103}

![Diagram illustrating the proposed mechanism of action of curcumin. Keap1, Kelch-like ECH-associated protein 1; Nrf2, nuclear factor (erythroid-derived 2)-like 2; HO-1, heme oxygenase-1; NQO-1, norvegicus NAD(P)H quinone dehydrogenase 1; GSH-Px, glutathione peroxidase; CAT, catalase; SOD1, superoxide dismutase 1; Streptozotocin; OS, oxidative stress.](MMR-17-01-0103-g03){#f4-mmr-17-01-0103}

###### 

Primers sequence and parameters.

  Primers   Genbank number   Primer sequence (5′→3′)   Orientation   Product (bp)   Annealing temperature (°C)
  --------- ---------------- ------------------------- ------------- -------------- ----------------------------
  β-actin   NM_031144.3      CACCATGTACCCAGGCATTG      Forward       229            59
                             ACAGTCCGCCTAGAAGCATT      Reverse                      
  CAT       NM_012520.2      ACACTTTGACAGAGAGCGGA      Forward       220            59
                             TTTCACTGCAAACCCACGAG      Reverse                      
  GSH-Px    S50336.1         GACCGACCCCAAGTACATCA      Forward       155            60
                             GCAGGGCTTCTATATCGGGT      Reverse                      
  HO-1      NM_012580.2      GATGGGTCCTCACACTCAGT      Forward       201            59
                             AAGGAAGACACAGGAAGGGG      Reverse                      
  NQO-1     NM_017000.3      ACCTCTCTGTGGTTTAGGGC      Forward       183            59
                             GGACCTGGGTGTGCTATGTA      Reverse                      
  SOD1      NM_017050.1      GCGTCATTCACTTCGAGCAG      Forward       204            60
                             GGTCTCCAACATGCCTCTCT      Reverse                      

CAT, catalase; NQO-1, NAD(P)H quinone dehydrogenase 1; GSH-Px, glutathione peroxidase; HO-1, heme oxygenase 1; SOD1, superoxide dismutase 1.

###### 

Concentrations of hepatic, myocardial and muscular glycogen in type 1 diabetic rats.

  Group      Hepatic (mg/g)                                                                                             Myocardial (mg/g)                                                                                          Muscular (mg/g)
  ---------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  NC         11.02±2.42                                                                                                 0.75±0.18                                                                                                  0.86±0.39
  DC         6.02±2.11^[b](#tfn4-mmr-17-01-0103){ref-type="table-fn"}^                                                  0.58±0.13^[a](#tfn3-mmr-17-01-0103){ref-type="table-fn"}^                                                  0.55±0.21^[a](#tfn3-mmr-17-01-0103){ref-type="table-fn"}^
  Diab-Cur   7.58±2.87^[a](#tfn3-mmr-17-01-0103){ref-type="table-fn"},[d](#tfn6-mmr-17-01-0103){ref-type="table-fn"}^   1.23±0.23^[a](#tfn3-mmr-17-01-0103){ref-type="table-fn"},[d](#tfn6-mmr-17-01-0103){ref-type="table-fn"}^   0.61±0.18^[a](#tfn3-mmr-17-01-0103){ref-type="table-fn"},[c](#tfn5-mmr-17-01-0103){ref-type="table-fn"}^

Results are from analyses using eighteen rats in each group. Data are presented as the mean ± standard error.

P\<0.05

P\<0.01 vs. NC group

P\<0.05

P\<0.01 vs. DC group. NC, negative control group; DC, diabetic control group; Diab-Cur, treatment group (fed a normal diet plus 1.0% curcumin).

###### 

Plasma antioxidant enzyme levels of superoxide dismutase, catalases and glutathione peroxidase and malondialdehyde.

  Group      SOD (U/ml)                                                                                                   GSH-Px (U/ml)                                                                                                    CAT (U/ml)                                                                                                   MDA (nmol/ml)
  ---------- ------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------
  NC         26.01±4.47                                                                                                   1,732.40±73.20                                                                                                   19.03±3.04                                                                                                   6.03±1.03
  DC         20.99±2.11^[b](#tfn9-mmr-17-01-0103){ref-type="table-fn"}^                                                   1,997.88±65.43^[c](#tfn10-mmr-17-01-0103){ref-type="table-fn"}^                                                  27.95±1.33^[b](#tfn9-mmr-17-01-0103){ref-type="table-fn"}^                                                   9.82±0.67^[c](#tfn10-mmr-17-01-0103){ref-type="table-fn"}^
  Diab-Cur   29.42±4.43^[a](#tfn8-mmr-17-01-0103){ref-type="table-fn"},[e](#tfn12-mmr-17-01-0103){ref-type="table-fn"}^   1,882.38±42.71^[a](#tfn8-mmr-17-01-0103){ref-type="table-fn"},[d](#tfn11-mmr-17-01-0103){ref-type="table-fn"}^   23.15±2.29^[a](#tfn8-mmr-17-01-0103){ref-type="table-fn"},[d](#tfn11-mmr-17-01-0103){ref-type="table-fn"}^   6.87±0.24^[a](#tfn8-mmr-17-01-0103){ref-type="table-fn"},[e](#tfn12-mmr-17-01-0103){ref-type="table-fn"}^

Results are from analyses using eighteen rats in each group. Data are presented as the mean ± standard error.

P\<0.05

P\<0.01

P\<0.001 mean statistically significant differences when compared with NC group

P\<0.05

P\<0.01 vs. DC group. NC, negative control group; DC, diabetic control group; Diab-Cur, treatment group (fed a normal diet plus 1.0% curcumin); SOD, superoxide dismutase; GSH-Px, glutathione peroxidase; CAT, catalases; MDA, malondialdehyde.
